Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19019161 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19018985 | 0.83 | ALDH1A1 (0.76) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19028009 | 0.82 | ALDH1A1 (0.75) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019160 | 0.82 | ALDH1A1 (0.75) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019244 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019162 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019173 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019174 | 0.77 | ALDH1A1 (0.66) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19018984 | 0.76 | ALDH1A1 (0.64) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL19019157 | 0.76 | ALDH1A1 (0.64) | ALDH1A1HPGDHSD17B10CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208000-B2 | Eis inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | ALDH1A1 819/4885HPGD 1286/4885HSD17B10 1502/4885 |
| US-10208000-B2 | Eis inhibitors | ABCC1, ATP5ME, ABCG2 | ALDH1A1 819/4885HPGD 1286/4885HSD17B10 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.